Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (281)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07223034 | A Study of 177Lu-PSMA-617 in People With Gliomas | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 |
| Jun 4, 2026 |
| clinicaltrials |
| NCT07274787 | Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma | not yet recruiting | N/A | 10 | University of CincinnatiOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627334 | Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN(ATTRACTION) | recruiting | N/A | 30 | Medical University of ViennaOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07628257 | Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up(GlioConnect) | not yet recruiting | N/A | 80 | Centre Paul StraussOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04780009 | Loupe-Based Intraoperative Fluorescence Imaging | recruiting | — | 30 | Guoqiang YuOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04978727 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 35 | Children's Oncology GroupNETWORK | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06533163 | Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial(OMX-EFS-01) | recruiting | N/A | 30 | BioTex, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07620548 | Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas | not yet recruiting | Phase 2 | 99 | Washington University School of MedicineOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT01269853 | Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | recruiting | Phase 1 / Phase 2 | 54 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01386710 | Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma | suspended | Phase 1 / Phase 2 | 54 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02861898 | Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 33 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03213002 | Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM(CAPTEM) | recruiting | Phase 1 / Phase 2 | 67 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03630289 | Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM | completed | N/A | 12 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03897491 | PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma | terminated | Phase 2 | 17 | photonamic GmbH & Co. KGINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04222309 | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) | suspended | Phase 1 | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05271240 | Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | recruiting | Phase 3 | 432 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05954858 | Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma | recruiting | N/A | 32 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05979064 | Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) | recruiting | N/A | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07616986 | LITT for Ultra-early GBM Recurrence | recruiting | N/A | 12 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05116137 | The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors(RESIST) | enrolling by invitation | N/A | 24 | Nova Scotia Health AuthorityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 6 | May 29, 2026 | clinicaltrials |
| NCT06831526 | Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma | recruiting | Early Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04752280 | Glioblastoma Radiotherapy Using IMRT or Proton Beams(GRIPS) | recruiting | N/A | 326 | University Hospital HeidelbergOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07605364 | Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer | not yet recruiting | Phase 2 / Phase 3 | 422 | Alliance for Clinical Trials in OncologyOTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT03688178 | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab(DERIVe) | active not recruiting | Phase 2 | 43 | Annick Desjardins, MDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05736406 | A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 12 | Hemerion TherapeuticsINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT07411690 | Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors(CSF-IMR) | recruiting | — | 200 | Medical University of WarsawOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07604285 | A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma(NOVA-GBM) | not yet recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07413796 | Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures(NEURO-SUTURE) | recruiting | N/A | 382 | Medical University of WarsawOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05500612 | MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy(MANGO) | recruiting | — | 20 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07590726 | PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors(PIRe) | not yet recruiting | N/A | 160 | Rigshospitalet, DenmarkOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT00906893 | Evaluation of [18F]-FMISO for Non Operated Glioblastoma(MISOGLIO) | completed | Phase 2 | 14 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04003649 | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | active not recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04477200 | Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma | active not recruiting | Phase 1 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04614909 | Study of Pamiparib in Newly Diagnosed and rGBM | completed | Early Phase 1 | 50 | Nader SanaiOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05281731 | Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma | recruiting | N/A | 40 | Washington University School of MedicineOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05773326 | Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG | terminated | Early Phase 1 | 5 | Nader SanaiOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07042620 | A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery | active not recruiting | N/A | 15 | SonoClear ASINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT02192359 | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03382977 | Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | terminated | Phase 1 / Phase 2 | 70 | VBI Vaccines Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06136611 | Preoperative Preradiotherapy TTFields(PORTRAIT) | recruiting | N/A | 42 | The Christie NHS Foundation TrustOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04015700 | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | active not recruiting | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | withdrawn | Phase 2 / Phase 3 | 0 | NRG OncologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT06796335 | Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired Brain Injury or Malignant Brain Tumour | completed | — | 35 | Rigshospitalet, DenmarkOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07284069 | Senicapoc and Perampanel for Newly Diagnosed Glioblastoma(SENIPERA) | recruiting | Early Phase 1 | 36 | Aarhus University HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02331498 | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme(PAZOGLIO) | active not recruiting | Phase 1 / Phase 2 | 51 | Centre Antoine LacassagneOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04699773 | LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138) | recruiting | N/A | 32 | University of Maryland, BaltimoreOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05557292 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | terminated | Phase 1 | 7 | Nicholas ButowskiOTHER | 1 | May 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2026source: clinicaltrials